research reports and media, page-2006

I have been wondering about this too and I'm sure it is covered off in earlier threads, but I went googling anyway.

I managed to find a document produced by the Australian Department of Health titled:

"Compounded medicines and good manufacturing practice (GMP) Guide to the interpretation of the PIC/S guide to GMP for compounded medicinal products" Version 3.0, September 2020

It is here FYI: https://consultations.health.gov.au/tga/compounded-medicines-and-gmp/supporting_documents/consultationcompoundedmedicinesandgoodmanufacturingpracticegmp.DOCX

This section appears relevant and would imply that Zilosul (once approved) would/should stop the compounding of injectable Elmiron

Appropriate circumstances for compounding medicines

Only prepare a compounded medicine in circumstances where:

•an appropriate commercial product is not available

•a commercial product is not suitable (e.g. if a patient experienced an allergy to an excipient in the commercial product), or

•when undertaking research sanctioned by a recognised human research ethics committee.

The compounding of a medicine (whether prescribed or not) should not take place when it would both:

•be a close formulation to an available and suitable commercial product

•would not be likely to produce a different therapeutic outcome to the commercial product.

In this situation, notify the prescriber that this medicine cannot be compounded under these circumstances.

DYOR - my thoughts only ;-)